Randomized Trial Hypothesized Methylergonovine Superiority Over Carboprost for Atonic Postpartum Hemorrhage
Background
Postpartum hemorrhage (PPH) remains a leading cause of maternal mortality worldwide, often due to uterine atony—the uterus failing to contract adequately after childbirth. First-line management typically involves oxytocin, alongside uterine massage and controlled cord traction. However, when oxytocin proves insufficient, clinicians must rely on second-line uterotonics. The comparative efficacy and safety profiles of these agents, such as ergot alkaloids and prostaglandins, are not always clearly established, leading to variations in clinical practice and an urgent need for evidence-based guidance to optimize patient outcomes.
Study Design
This study was designed as a randomized clinical trial to compare the efficacy of two second-line uterotonics, methylergonovine and carboprost, in treating atonic postpartum hemorrhage. The investigators hypothesized that methylergonovine would induce superior uterine tone compared to carboprost. The trial intended to enroll participants experiencing PPH due to uterine atony, randomly assigning them to receive one of the two interventions. The primary endpoint was planned to be the assessment of uterine tone. However, the trial was unfortunately withdrawn prior to any participant enrollment.
Results
This randomized clinical trial, registered as NCT01710566, was unfortunately withdrawn before any participants could be enrolled. Consequently, no data on the comparative efficacy or safety of methylergonovine versus carboprost in treating atonic postpartum hemorrhage were generated or reported. The study's hypothesis, which posited that methylergonovine would produce superior uterine tone compared to carboprost, therefore remains untested by this specific trial. Without participant data, no statistical analyses, p-values, or effect sizes could be calculated or presented.
The trial was withdrawn prior to enrollment, meaning no clinical data comparing methylergonovine and carboprost for atonic PPH were collected.
Why It Matters
The question this trial aimed to answer remains critically important for maternal health globally. Postpartum hemorrhage is a life-threatening obstetric emergency, and clear evidence on the most effective second-line uterotonics is essential for guiding clinical practice and improving patient outcomes when first-line agents like oxytocin fail. The absence of comparative data for agents like methylergonovine and carboprost means clinicians must often rely on institutional protocols or individual experience, rather than robust evidence. Further randomized trials are urgently needed to establish the optimal sequence and choice of second-line uterotonics to minimize maternal morbidity and mortality. This research gap directly impacts the development of standardized, evidence-based protocols for managing severe PPH.
postpartum-hemorrhage
pph
uterotonics
methylergonovine
carboprost
randomized-clinical-trial